GLP-1 Medications and Pregnancy: What You Need to Know About Family Planning, Fertility, and Safe Discontinuation

All GLP-1 receptor agonists, including semaglutide and tirzepatide, carry FDA pregnancy category warnings and are contraindicated during pregnancy. This contraindication is based on animal reproduction studies that demonstrated adverse developmental effects in offspring exposed to GLP-1 agonists during gestation. In animal studies conducted at doses several times the maximum recommended human dose, semaglutide was associated with embryo-fetal toxicity, including increased rates of skeletal malformations, reduced fetal growth, and pregnancy loss.

While animal reproductive toxicology does not always predict human effects, the absence of adequate and well-controlled human pregnancy studies means the potential risk to a human fetus cannot be ruled out. The mechanism of concern involves both the direct pharmacological effects of GLP-1 receptor activation on developing tissues and the indirect effects of significant caloric restriction and weight loss during pregnancy, which can impair fetal growth and development regardless of the cause.

Pregnancy itself is a state of increased caloric and nutritional demand. The appetite suppression and reduced food intake produced by GLP-1 medications are directly opposed to the metabolic requirements of pregnancy. Inadequate maternal weight gain during pregnancy is associated with increased risk of low birth weight, preterm delivery, and neonatal complications. For these combined reasons, the clinical standard of care requires discontinuation of GLP-1 therapy before conception and throughout pregnancy.

Women of reproductive age starting GLP-1 therapy through Weight Method or any other provider should have a clear understanding of their pregnancy planning timeline and must use effective contraception consistently throughout the duration of GLP-1 treatment.

The washout period, the recommended time between the last dose of a GLP-1 medication and attempting conception, varies by specific medication and is determined by the drug's pharmacokinetic properties. For semaglutide, which has a half-life of approximately one week, the recommended washout period is at least two months (approximately eight to nine half-lives) before attempting to conceive. This allows semaglutide to be essentially eliminated from the body before conception occurs.

For tirzepatide, which has a half-life of approximately five days, the recommended washout period is similarly at least two months before planned conception. While tirzepatide clears the body somewhat faster than semaglutide based on half-life alone, the two-month recommendation provides a conservative safety margin that accounts for individual pharmacokinetic variability and ensures negligible residual drug levels at the time of conception.

For comparison, shorter-acting GLP-1 agonists like liraglutide (half-life 13 hours) require a shorter washout period of approximately two weeks, and exenatide (half-life 2.4 hours) clears within days of discontinuation. However, these shorter-acting agents are less commonly used for weight management than semaglutide and tirzepatide.

The practical planning timeline for a woman on GLP-1 therapy who wants to become pregnant involves several steps: discuss pregnancy planning with her prescriber at least three months before the desired conception date, begin the GLP-1 taper and discontinuation process, complete the two-month washout period, confirm adequate folate supplementation and prenatal care initiation, and only then begin attempting conception. Women who discover they are pregnant while on GLP-1 therapy should discontinue the medication immediately and contact their obstetric provider.

While GLP-1 medications must be discontinued before pregnancy, the weight loss achieved through pre-conception GLP-1 therapy can significantly improve fertility outcomes and pregnancy health. Obesity is one of the most common modifiable risk factors for both female and male infertility. In women, excess adiposity disrupts the hypothalamic-pituitary-ovarian axis, leading to anovulatory cycles, polycystic ovarian syndrome (PCOS), reduced IVF success rates, and increased miscarriage risk.

Weight loss of 5 to 10 percent of body weight has been shown to restore ovulatory function in up to 80 percent of anovulatory women with obesity. For women with PCOS, even modest weight loss improves menstrual regularity, reduces hyperandrogenism, and increases both spontaneous conception rates and IVF success rates. The magnitude of weight loss typically achieved with GLP-1 therapy (15 to 22 percent of body weight) substantially exceeds the threshold needed for fertility improvement, positioning GLP-1 treatment as a powerful pre-conception intervention for women with obesity-related infertility.

Maternal obesity is also associated with increased pregnancy complications including gestational diabetes, preeclampsia, cesarean delivery, macrosomia, and neural tube defects. Women who achieve a lower BMI before conception through GLP-1-assisted weight loss reduce their risk for each of these complications. The American College of Obstetricians and Gynecologists recommends pre-conception weight loss counseling for women with BMI above 30, and GLP-1 therapy followed by appropriate washout represents one of the most effective pathways to achieving this goal.

Anecdotal reports of increased fertility during GLP-1 therapy, sometimes called Ozempic babies, highlight the importance of reliable contraception throughout treatment. Women who are not actively planning pregnancy should use effective contraception while on GLP-1 therapy, as improved metabolic health and weight loss can restore fertility more quickly than anticipated.

The safety of GLP-1 medications during breastfeeding has not been established through human clinical studies. Animal data shows that semaglutide and tirzepatide are excreted in breast milk at low concentrations, though the effects on the nursing infant are unknown. Given the lack of human lactation data, the FDA labeling for both medications recommends considering the benefits of breastfeeding and the mother's need for medication when making treatment decisions.

Clinically, most prescribers advise against using GLP-1 agonists during active breastfeeding, particularly during the first six months when breast milk is the primary source of infant nutrition. The concern is twofold: potential direct exposure of the infant to the drug through breast milk, and the effect of appetite suppression on maternal caloric intake and breast milk production. Inadequate maternal caloric intake can reduce milk volume and alter milk composition, potentially affecting infant growth and development.

For postpartum women who wish to resume GLP-1 therapy after breastfeeding, the transition can typically begin once exclusive breastfeeding has ended or once the infant is receiving sufficient nutrition from complementary foods and formula. Many women choose to resume GLP-1 therapy three to six months postpartum if they are not breastfeeding, or after weaning if they are.

Postpartum weight management is a clinically important consideration, as approximately 75 percent of women retain at least some pregnancy-related weight gain at one year postpartum, and those who entered pregnancy with obesity are at highest risk for significant long-term weight retention. Weight Method's clinical team can help postpartum patients develop an appropriate timeline for resuming GLP-1 therapy based on their breastfeeding status, reproductive plans, and weight management goals.

Reliable contraception is not optional for women of reproductive age on GLP-1 therapy; it is a medical requirement given the medication's pregnancy contraindication. The choice of contraceptive method is particularly important because GLP-1 medications can affect the absorption of oral contraceptives through delayed gastric emptying, as discussed in drug interaction literature.

The most reliable contraceptive options for women on GLP-1 therapy are long-acting reversible contraceptives (LARCs) that bypass gastrointestinal absorption entirely. These include intrauterine devices (hormonal IUD such as Mirena or Kyleena, or copper IUD such as Paragard), the subdermal etonogestrel implant (Nexplanon), and depot medroxyprogesterone acetate (Depo-Provera) injection. Each of these methods has a failure rate below 1 percent with typical use and is unaffected by GLP-1-mediated gastric slowing.

For women who prefer oral contraceptives, combined estrogen-progestin pills are a reasonable option with the awareness that peak absorption may be delayed. Progestin-only minipills, which have a narrower efficacy window, are generally less ideal during GLP-1 therapy due to the greater sensitivity to absorption timing. Non-oral hormonal methods including the contraceptive patch and vaginal ring are also unaffected by gastric absorption changes.

The recommended family planning timeline for women on GLP-1 therapy who wish to conceive is as follows. Three to six months before desired conception, discuss your timeline with your Weight Method provider or prescriber. Two to three months before conception, begin tapering and discontinuing the GLP-1 medication. During the two-month washout period, start prenatal vitamins with adequate folate (at least 400 mcg daily), optimize any other medications for pregnancy compatibility, and schedule a pre-conception visit with your obstetric provider. After the washout is complete and any residual GI effects have resolved, begin attempting conception. This structured approach maximizes the fertility benefits of weight loss while ensuring safe discontinuation before pregnancy.